Latest 10-K annual reports

Miller Industries reports a significant decline in net sales and net income for fiscal 2025, driven by demand headwinds and production cuts, despite strategic acquisition of Omars S.p.A. and increased dividend.

Westwood Holdings Group announced a significant increase in net income for 2025, driven by higher average assets under management and strong performance in several key investment strategies.

Aquestive Therapeutics reports a significant net loss increase and a delay in Anaphylm's FDA approval, alongside a legal setback for Libervant, despite successful capital raises.

Sight Sciences reports a net loss of $38.4 million for 2025, with flat Interventional Glaucoma revenue and a significant decline in Interventional Dry Eye sales, alongside a 20% workforce reduction.

Orion Group Holdings, Inc. reported a return to net income in 2025 with 7% revenue growth, while strategically acquiring J.E. McAmis, Inc. to bolster its marine construction capabilities.

CompX International reported a significant rebound in operating income and net sales for 2025, driven by strong performance in both Security Products and Marine Components segments, with modest growth anticipated for 2026.

PepGen Inc. reports on its 2025 fiscal year, highlighting the advancement of its lead DM1 candidate PGN-EDODM1 into Phase 2 trials, despite an FDA partial clinical hold, and the discontinuation of its DMD program.

Rigetti Computing reports increased net losses in 2025 despite significant technological advancements in quantum computing and a substantial capital raise.

Atlas Lithium Corporation reported a significantly reduced net loss for fiscal year 2025, driven by lower stock-based compensation and exploration costs, as it progresses its Minas Gerais Lithium Project towards production.

A SPAC III Acquisition Corp. reports its 2025 annual results, detailing a terminated deal, a new merger agreement with Bioserica, significant shareholder redemptions, and an extended business combination deadline to November 2026.

Janus International Group, Inc. reported a significant decline in total revenues and net income for the fiscal year ended January 3, 2026, primarily driven by macroeconomic uncertainty and elevated interest rates.

Grocery Outlet Holding Corp. reported a significant net loss for fiscal 2025, driven by substantial impairment charges and restructuring efforts, while also announcing plans to close 36 underperforming stores.

Keros Therapeutics achieved net income in 2025 driven by a Takeda licensing deal, while progressing lead candidates rinvatercept and elritercept, and executing a significant capital return program.

SCYNEXIS, Inc. reported a net loss of $8.6 million for FY2025, terminated the MARIO study with GSK for a $24.8 million payment, and is advancing its second-generation antifungal SCY-247 into Phase 1 IV and Phase 2 oral trials.

Niagen Bioscience, Inc. reported significant revenue and net income growth in 2025, driven by strong Tru Niagen and ingredient sales, alongside strategic intellectual property and segment divestiture actions.

Bankwell Financial Group reported a significant increase in net income and improved asset quality for the fiscal year ended December 31, 2025, driven by higher revenues and reduced credit loss provisions.

The United States 12 Month Natural Gas Fund, LP (UNL) filed its annual 10-K report for the fiscal year ended December 31, 2025, detailing its investment strategy, financial performance, and operational risks within a dynamic natural gas market.

Oil States International, Inc. reported a net loss of $109.4 million for the fiscal year ended December 31, 2025, driven by significant asset impairments and U.S. land-based operational restructuring.

First Financial Corporation announced a significant increase in net income for 2025, driven by organic growth, despite a decrease in total deposits and an increase in non-performing loans.

Westlake Chemical Partners LP reported a decrease in net income and cash flow for 2025, primarily driven by higher feedstock costs and extended turnaround activities, despite a slight increase in net sales.

Sensus Healthcare, Inc. reported a net loss of $7.7 million in 2025, a significant decline from the prior year's profit, driven by reduced sales and increased operating expenses.

Ocugen, Inc. reported increased net losses and a going concern warning for 2025, despite advancing its gene therapy pipeline with positive clinical data and regulatory milestones.

SunOpta Inc. announced significant revenue and profit growth for fiscal year 2025, alongside an impending acquisition by Refresco for $6.50 per share, expected to close in Q2 2026.

Alerus Financial Corporation reported a slight decrease in net income for 2025 to $17.4 million, primarily due to a $68.4 million loss from a strategic investment securities repositioning, despite strong net interest income growth and asset expansion.

SmartRent, Inc. announced a significant increase in net losses and a decrease in total revenue for the fiscal year ended December 31, 2025, alongside a substantial goodwill impairment charge.

Advanced Flower Capital Inc. completed its strategic conversion to a Business Development Company effective January 1, 2026, following a challenging 2025 marked by a significant net loss and loan write-offs.

TScan Therapeutics reports increased net losses in 2025, strategically prioritizes its hematologic malignancies program, and pauses solid tumor trial enrollment to focus on in vivo engineering.

Cellectar Biosciences reports significant losses and a going concern warning for 2025, despite positive clinical data for iopofosine I 131 and other PDC programs.

Altisource Portfolio Solutions S.A. reported a significant improvement in net income and earnings per share for 2025, driven by a major debt exchange transaction and a substantial tax benefit, despite ongoing customer concentration risks.

Gran Tierra Energy Inc. reported a net loss of $193.1 million in 2025, driven by a significant non-cash impairment in Canada and Colombia, despite increased production volumes.